Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study-Reference-Cited by-同舟云学术

Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

Published:2024-09 Issue:9 Volume:9 Page:103690
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Rodriguez-Vida A.,Valderrama B.P.,Castellano D.,Pinto A.,Mellado B.,Puente J.,Climent M.A.,Domenech M.,Vazquez F.,Perez-Gracia J.L.,Bonfill T.,Morales-Barrera R.,Gonzalez-Billalabeitia E.,Garcia-del-Muro X.,Maroto P.,Navarro-Gorro N.,Juanpere N.,Juan O.,Bellmunt J.^ORCID

Funder

Pfizer

Institut Hospital del Mar d'Investigacions Mèdiques

Merck

Roche

Astellas Pharma US

Publisher

Elsevier BV

Reference17 articles.

1. LAB6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC);Powles;Ann Oncol,2023

2. Treatment of metastatic urothelial cancer in 2018;Bellmunt;JAMA Oncol,2019

3. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy;Galsky;J Clin Oncol,2011

4. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J Clin Oncol,2012

5. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial;Dogliotti;Eur Urol,2007